Circulating microRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study.

CONCLUSIONS: The plasma MSC test could supplement PD-L1 tumor expression to identify a subgroup of advanced lung cancer patients with worse ORR, PFS and OS in immunotherapy regimens.
PMID: 30617131 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 7, 2019 Category: Cancer & Oncology Authors: Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G Tags: Clin Cancer Res Source Type: research